OncoMatch/Clinical Trials/NCT07209059
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
Is NCT07209059 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Nivolumab for hodgkin lymphoma.
Treatment: Nivolumab — This is a single-center, open-label, phase 2 pilot study evaluating the efficacy and safety of a response-adapted first-line treatment strategy for patients with classical Hodgkin lymphoma (cHL) and unfavorable prognostic factors. The FINISH protocol (First-line Immuno-chemotherapy Navigated by Interim PET for Stratification and Hazard minimization In Hodgkin lymphoma) integrates nivolumab into induction therapy and tailors subsequent treatment based on interim PET-CT response. The study also includes exploratory monitoring of circulating tumor DNA (ctDNA) to investigate its role in early response assessment and residual disease detection.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Hodgkin Lymphoma
Disease stage
Required: Stage IIB (BULKY), III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: chemotherapy
No prior chemotherapy, radiotherapy, or immunotherapy for lymphoma
Cannot have received: radiation therapy
No prior chemotherapy, radiotherapy, or immunotherapy for lymphoma
Cannot have received: immunotherapy
No prior chemotherapy, radiotherapy, or immunotherapy for lymphoma
Lab requirements
Kidney function
Serum creatinine ≤ 0.2 mmol/L; severe renal impairment (serum creatinine > 0.2 mmol/L) excluded unless lymphoma-related
Liver function
Absence of severe hepatic dysfunction; severe hepatic dysfunction excluded unless directly related to lymphoma
Cardiac function
Absence of severe cardiac dysfunction; congestive heart failure, unstable angina, recent myocardial infarction, or severe cardiac arrhythmias excluded
Adequate organ function, including: Serum creatinine ≤ 0.2 mmol/L; Absence of severe cardiac, pulmonary, hepatic, or renal dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07209059 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IIB (BULKY) or III or IV is required.
Is there an age limit?
Yes. Patients must be 60 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages